{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-036766","form_type":"8-K","ticker":"AMRN","cik":"0000897448","company_name":"AMARIN CORP PLCUK","filed_at":"2023-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.962340+00:00","generated_at":"2026-06-12T15:59:13.906898+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Amarin Q2 revenue $80M (-15%); net loss narrows to $17.6M; lowers 2023 opex guidance","bullets":["Total net revenue $80.2M (-15% YoY); net product revenue $65.2M (-31% YoY) due to generic competition.","GAAP net loss $17.6M ($0.04 loss per share) vs $70.0M loss ($0.18 loss) in Q2 2022; non-GAAP adjusted net income $8.6M.","Cash and investments $313M; generated positive cash flow of $9M during the quarter.","Lowering 2023 operating expense guidance to $240-250M from $270-285M; cost reduction plan savings $40M over 12 months.","Spain's drug pricing committee recommended national reimbursement of VAZKEPA; regulatory approvals in China and Saudi Arabia."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-036766","json":"https://secwatch.observer/filing/0000950170-23-036766.json","markdown":"https://secwatch.observer/filing/0000950170-23-036766.md","text":"https://secwatch.observer/filing/0000950170-23-036766.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/897448/000095017023036766/0000950170-23-036766-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/897448/000095017023036766/amrn-20230802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T15:59:13.906898+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1b191d451305f973fd0bc69e3f7e1a02296bb4a7","claim":"AMARIN CORP PLCUK reported three months ended June 30, 2023 results: revenue Net product revenue for the three months ended June 30, 2023, was $65.2 million.","evidence_excerpt":"Total net revenue for the three months ended June 30, 2023, was $80.2 million, compared to $94.4 million in the corresponding period of 2022, a decrease of 15%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/897448/000095017023036766/0000950170-23-036766-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended June 30, 2023"},{"label":"Revenue","value":"Net product revenue for the three months ended June 30, 2023, was $65.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"1b191d451305f973fd0bc69e3f7e1a02296bb4a7","claim":"AMARIN CORP PLCUK reported three months ended June 30, 2023 results: revenue Net product revenue for the three months ended June 30, 2023, was $65.2 million.","evidence_excerpt":"Net product revenue for the three months ended June 30, 2023, was $65.2 million, compared to $93.8 million in the corresponding period of 2022, a decrease of 31%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/897448/000095017023036766/0000950170-23-036766-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended June 30, 2023"},{"label":"Revenue","value":"Net product revenue for the three months ended June 30, 2023, was $65.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}